A Glimpse Into The Expert Outlook On Enfusion Through 4 Analysts
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Enfusion (NYSE:ENFN) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 1 | 2 | 1 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 1 |
| 2M Ago | 0 | 0 | 0 | 1 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Enfusion, presenting an average target of $9.0, a high estimate of $10.00, and a low estimate of $8.00. A decline of 2.7% from the prior average price target is evident in the current average.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Enfusion is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Koji Ikeda | B of A Securities | Raises | Underperform | $9.00 | $8.00 |
| Gabriela Borges | Goldman Sachs | Lowers | Sell | $8.00 | $9.00 |
| Alexei Gogolev | JP Morgan | Lowers | Underweight | $9.00 | $11.00 |
| Sumeet Mody | Piper Sandler | Raises | Neutral | $10.00 | $9.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enfusion. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Enfusion compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Enfusion's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Enfusion's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Enfusion analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Enfusion's Background
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Enfusion: Financial Performance Dissected
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Enfusion's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 13.3%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Enfusion's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enfusion's ROE stands out, surpassing industry averages. With an impressive ROE of 3.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Enfusion's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: Enfusion's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.